FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ARRB1-GDPD5

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ARRB1-GDPD5
FusionPDB ID: 6838
FusionGDB2.0 ID: 6838
HgeneTgene
Gene symbol

ARRB1

GDPD5

Gene ID

408

81544

Gene namearrestin beta 1glycerophosphodiester phosphodiesterase domain containing 5
SynonymsARB1|ARR1GDE2|PP1665
Cytomap

11q13.4

11q13.4-q13.5

Type of geneprotein-codingprotein-coding
Descriptionbeta-arrestin-1arrestin 2non-visual arrestin-2glycerophosphodiester phosphodiesterase domain-containing protein 5glycerophosphodiester phosphodiesterase 2
Modification date2020031320200313
UniProtAcc

P49407

Main function of 5'-partner protein: FUNCTION: Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes. During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adapter protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Involved in internalization of P2RY4 and UTP-stimulated internalization of P2RY2. Involved in phosphorylation-dependent internalization of OPRD1 ands subsequent recycling. Involved in the degradation of cAMP by recruiting cAMP phosphodiesterases to ligand-activated receptors. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G-protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2). ERK1/2 activated by the beta-arrestin scaffold is largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Recruits c-Src/SRC to ADRB2 resulting in ERK activation. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Inhibits ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Is required for SP-stimulated endocytosis of NK1R and recruits c-Src/SRC to internalized NK1R resulting in ERK1/2 activation, which is required for the antiapoptotic effects of SP. Is involved in proteinase-activated F2RL1-mediated ERK activity. Acts as signaling scaffold for the AKT1 pathway. Is involved in alpha-thrombin-stimulated AKT1 signaling. Is involved in IGF1-stimulated AKT1 signaling leading to increased protection from apoptosis. Involved in activation of the p38 MAPK signaling pathway and in actin bundle formation. Involved in F2RL1-mediated cytoskeletal rearrangement and chemotaxis. Involved in AGTR1-mediated stress fiber formation by acting together with GNAQ to activate RHOA. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. May serve as nuclear messenger for GPCRs. Involved in OPRD1-stimulated transcriptional regulation by translocating to CDKN1B and FOS promoter regions and recruiting EP300 resulting in acetylation of histone H4. Involved in regulation of LEF1 transcriptional activity via interaction with DVL1 and/or DVL2 Also involved in regulation of receptors other than GPCRs. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN. Binds phosphoinositides. Binds inositolhexakisphosphate (InsP6) (By similarity). Involved in IL8-mediated granule release in neutrophils. Required for atypical chemokine receptor ACKR2-induced RAC1-LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for the up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. Involved in the internalization of the atypical chemokine receptor ACKR3. Negatively regulates the NOTCH signaling pathway by mediating the ubiquitination and degradation of NOTCH1 by ITCH. Participates in the recruitment of the ubiquitin-protein ligase to the receptor (PubMed:23886940). {ECO:0000250, ECO:0000269|PubMed:12464600, ECO:0000269|PubMed:14711824, ECO:0000269|PubMed:15475570, ECO:0000269|PubMed:15611106, ECO:0000269|PubMed:15671180, ECO:0000269|PubMed:15878855, ECO:0000269|PubMed:16144840, ECO:0000269|PubMed:16280323, ECO:0000269|PubMed:16378096, ECO:0000269|PubMed:16492667, ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:18337459, ECO:0000269|PubMed:18419762, ECO:0000269|PubMed:19620252, ECO:0000269|PubMed:19643177, ECO:0000269|PubMed:22457824, ECO:0000269|PubMed:23341447, ECO:0000269|PubMed:23633677, ECO:0000269|PubMed:23886940}.

Q8WTR4

Main function of 5'-partner protein: FUNCTION: Glycerophosphodiester phosphodiesterase that promotes neurite formation and drives spinal motor neuron differentiation (By similarity). Mediates the cleavage of glycosylphosphatidylinositol (GPI) anchor of target proteins: removes the GPI-anchor of RECK, leading to release RECK from the plasma membrane (By similarity). May contribute to the osmotic regulation of cellular glycerophosphocholine (By similarity). {ECO:0000250|UniProtKB:Q3KTM2, ECO:0000250|UniProtKB:Q640M6}.
Ensembl transtripts involved in fusion geneENST idsENST00000360025, ENST00000393505, 
ENST00000420843, 
ENST00000336898, 
ENST00000376282, ENST00000529095, 
ENST00000529721, ENST00000443276, 
ENST00000526177, ENST00000533784, 
ENST00000533805, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score18 X 10 X 9=16209 X 7 X 7=441
# samples 2314
** MAII scorelog2(23/1620*10)=-2.81628804682761
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(14/441*10)=-1.65535182861255
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ARRB1 [Title/Abstract] AND GDPD5 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ARRB1 [Title/Abstract] AND GDPD5 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ARRB1(75062632)-GDPD5(75201365), # samples:4
Anticipated loss of major functional domain due to fusion event.ARRB1-GDPD5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ARRB1-GDPD5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ARRB1-GDPD5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ARRB1-GDPD5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ARRB1-GDPD5 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
ARRB1-GDPD5 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
ARRB1-GDPD5 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneARRB1

GO:0031397

negative regulation of protein ubiquitination

16378096

HgeneARRB1

GO:0032088

negative regulation of NF-kappaB transcription factor activity

16378096

HgeneARRB1

GO:0032715

negative regulation of interleukin-6 production

16378096

HgeneARRB1

GO:0032717

negative regulation of interleukin-8 production

16378096

HgeneARRB1

GO:0070374

positive regulation of ERK1 and ERK2 cascade

10644702



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:75062632/chr11:75201365)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ARRB1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across GDPD5 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000420843ARRB1chr1174993005-ENST00000336898GDPD5chr1175173934-3080512322212726
ENST00000393505ARRB1chr1174993005-ENST00000336898GDPD5chr1175173934-3204636212336771
ENST00000360025ARRB1chr1174993005-ENST00000336898GDPD5chr1175173934-3080512322212726
ENST00000420843ARRB1chr1174993006-ENST00000336898GDPD5chr1175173934-3080512322212726
ENST00000393505ARRB1chr1174993006-ENST00000336898GDPD5chr1175173934-3204636212336771
ENST00000360025ARRB1chr1174993006-ENST00000336898GDPD5chr1175173934-3080512322212726
ENST00000420843ARRB1chr1175062632-ENST00000336898GDPD5chr1175173934-2686118161818600
ENST00000393505ARRB1chr1175062632-ENST00000336898GDPD5chr1175173934-2810242441942632
ENST00000360025ARRB1chr1175062632-ENST00000336898GDPD5chr1175173934-2686118161818600

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000420843ENST00000336898ARRB1chr1174993005-GDPD5chr1175173934-0.013272040.986728
ENST00000393505ENST00000336898ARRB1chr1174993005-GDPD5chr1175173934-0.0130032650.98699677
ENST00000360025ENST00000336898ARRB1chr1174993005-GDPD5chr1175173934-0.013272040.986728
ENST00000420843ENST00000336898ARRB1chr1174993006-GDPD5chr1175173934-0.013272040.986728
ENST00000393505ENST00000336898ARRB1chr1174993006-GDPD5chr1175173934-0.0130032650.98699677
ENST00000360025ENST00000336898ARRB1chr1174993006-GDPD5chr1175173934-0.013272040.986728
ENST00000420843ENST00000336898ARRB1chr1175062632-GDPD5chr1175173934-0.0610258730.93897414
ENST00000393505ENST00000336898ARRB1chr1175062632-GDPD5chr1175173934-0.0574561470.9425438
ENST00000360025ENST00000336898ARRB1chr1175062632-GDPD5chr1175173934-0.0610258730.93897414

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ARRB1-GDPD5

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ARRB1chr1174993005GDPD5chr1175173934512160SVTLQPGPEDTGKWERLWFLLLTFTF
ARRB1chr1174993005GDPD5chr1175173934636205SVTLQPGPEDTGKWERLWFLLLTFTF
ARRB1chr1174993006GDPD5chr1175173934512160SVTLQPGPEDTGKWERLWFLLLTFTF
ARRB1chr1174993006GDPD5chr1175173934636205SVTLQPGPEDTGKWERLWFLLLTFTF
ARRB1chr1175062632GDPD5chr117517393411834PATVADHGRQRDPWERLWFLLLTFTF
ARRB1chr1175062632GDPD5chr117517393424266PATVADHGRQRDPWERLWFLLLTFTF

Top

Potential FusionNeoAntigen Information of ARRB1-GDPD5 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ARRB1-GDPD5_74993005_75173934.msa
ARRB1-GDPD5_75062632_75173934.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B27:07GKWERLWFL0.99030.64871120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B57:01DTGKWERLW0.98120.9786918
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B58:01DTGKWERLW0.95040.9639918
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B58:02DTGKWERLW0.94720.9646918
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B48:01GKWERLWFL0.44990.81931120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B53:01QPGPEDTGKW0.79790.7903414
ARRB1-GDPD5chr1174993005chr1175173934512HLA-C07:95GKWERLWFL0.98490.67221120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-C07:05GKWERLWFL0.96230.96441120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B44:04PEDTGKWERLW0.99960.5616718
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B27:08GKWERLWFL0.99240.69331120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B27:06GKWERLWFL0.99180.71991120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-C07:01GKWERLWFL0.98770.64991120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B27:09GKWERLWFL0.98480.70681120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B57:10DTGKWERLW0.98120.9786918
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B57:04DTGKWERLW0.85420.9068918
ARRB1-GDPD5chr1174993005chr1175173934512HLA-C06:08GKWERLWFL0.47390.99291120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-C06:02GKWERLWFL0.2830.99431120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-C06:17GKWERLWFL0.2830.99431120
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B53:02QPGPEDTGKW0.7520.7669414
ARRB1-GDPD5chr1174993005chr1175173934512HLA-B15:24LQPGPEDTGKW0.99990.9656314
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B48:01RQRDPWERL0.99610.6407817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:05QRDPWERLW0.99450.5914918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:01RQRDPWERL0.99380.922817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:04QRDPWERLW0.99170.7262918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:07RQRDPWERL0.97560.5962817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B35:03DPWERLWFL0.950.85261120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B51:01DPWERLWFL0.94420.54161120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A30:08RQRDPWERL0.94380.8086817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B35:02DPWERLWFL0.86920.93991120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B35:04DPWERLWFL0.86920.93991120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B08:01DPWERLWFL0.84050.88261120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B58:02QRDPWERLW0.82610.9913918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:03RQRDPWERL0.77650.8804817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B38:01QRDPWERLW0.74930.9939918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B38:02QRDPWERLW0.73150.9937918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B08:09DPWERLWFL0.70960.86611120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B39:13RQRDPWERL0.67780.9589817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B13:02RQRDPWERL0.63540.8082817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B07:10RQRDPWERL0.62620.6655817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A32:13RQRDPWERL0.58720.9226817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B13:01RQRDPWERL0.58360.9733817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B52:01RQRDPWERL0.01680.9521817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:05GRQRDPWERL0.99970.6463717
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:07GRQRDPWERL0.99940.5598717
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:07QRDPWERLWF0.99910.7545919
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B57:01RQRDPWERLW0.99830.9905818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B58:02RQRDPWERLW0.99420.9772818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A31:08RQRDPWERLW0.98390.7774818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B58:01RQRDPWERLW0.97670.964818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B81:01RDPWERLWFL0.83240.76931020
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A32:13RQRDPWERLW0.82630.9682818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B13:01RQRDPWERLW0.73590.9608818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:07QRDPWERLWFL0.99980.8129920
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B58:01VADHGRQRDPW0.99950.9152314
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:14GRQRDPWER0.99790.5177716
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:04RQRDPWERL0.97790.9522817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:07RQRDPWERL0.97040.8081817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:03QRDPWERLW0.95920.6077918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:95QRDPWERLW0.94440.8489918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B78:01DPWERLWFL0.93550.69851120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B42:02DPWERLWFL0.92210.88561120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:05QRDPWERLW0.90150.9759918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:19QRDPWERLW0.88060.9366918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B42:01DPWERLWFL0.8770.87691120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B35:12DPWERLWFL0.86920.93991120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:27QRDPWERLW0.85630.9757918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B39:08RQRDPWERL0.81810.8887817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:10QRDPWERLW0.80310.9897918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:67QRDPWERLW0.77960.9859918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:80QRDPWERLW0.77960.9859918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B39:10DPWERLWFL0.4620.96821120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:95QRDPWERLWF0.99760.905919
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:03QRDPWERLWF0.99280.5809919
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B44:08RQRDPWERLW0.87930.7113818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:07RQRDPWERLWF0.99940.8028819
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C18:01QRDPWERL0.99950.9023917
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B53:02DPWERLWF0.98330.59621119
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B18:07DPWERLWF0.94250.8841119
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:10GRQRDPWER0.99670.676716
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:135RQRDPWERL0.99420.9248817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:125RQRDPWERL0.99380.922817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:33RQRDPWERL0.99380.922817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:34RQRDPWERL0.99380.922817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:27RQRDPWERL0.99280.9274817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:24RQRDPWERL0.99270.9457817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:50RQRDPWERL0.99190.9233817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:10QRDPWERLW0.99170.7741918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:06RQRDPWERL0.98380.8198817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:09RQRDPWERL0.97160.7273817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B35:24DPWERLWFL0.96660.86241120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:35RQRDPWERL0.96530.9142817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B51:09DPWERLWFL0.96420.55661120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:73RQRDPWERL0.96130.9549817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:01QRDPWERLW0.95680.8232918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B78:02DPWERLWFL0.94540.78431120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B51:06DPWERLWFL0.94240.52581120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A30:01RQRDPWERL0.94240.9125817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B53:02DPWERLWFL0.940.53841120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A32:01RQRDPWERL0.93740.9529817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:12RQRDPWERL0.93560.8732817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:30RQRDPWERL0.90720.9438817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:53RQRDPWERL0.90190.9113817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B59:01DPWERLWFL0.87370.53751120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B35:09DPWERLWFL0.86920.93991120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B39:02RQRDPWERL0.84780.955817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B08:18DPWERLWFL0.84050.88261120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B55:04DPWERLWFL0.82840.52351120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:68RQRDPWERL0.81260.7695817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:54RQRDPWERL0.80240.9059817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B48:05RQRDPWERL0.79420.5871817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:02QRDPWERLW0.77960.9859918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:22QRDPWERLW0.75030.8379918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B38:05QRDPWERLW0.74930.9939918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:39RQRDPWERL0.71560.9022817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A02:14RQRDPWERL0.69290.5637817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B40:21RQRDPWERL0.66090.591817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B07:13RQRDPWERL0.61850.9117817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B18:07DPWERLWFL0.58560.84981120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B08:12DPWERLWFL0.57620.89931120
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B48:02RQRDPWERL0.55420.9737817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C06:06QRDPWERLW0.350.9928918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B35:28RQRDPWERL0.24630.977817
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C06:02QRDPWERLW0.00460.9973918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C06:17QRDPWERLW0.00460.9973918
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:08GRQRDPWERL0.99970.5746717
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:06GRQRDPWERL0.99940.7873717
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:09GRQRDPWERL0.99920.6443717
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:09QRDPWERLWF0.9990.605919
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:24RQRDPWERLW0.99870.9314818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B57:10RQRDPWERLW0.99830.9905818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-C07:01QRDPWERLWF0.9980.8614919
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B57:04RQRDPWERLW0.99780.79818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B58:06RQRDPWERLW0.99270.9561818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B57:02RQRDPWERLW0.98380.9674818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:68RQRDPWERLW0.97860.7822818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-A32:01RQRDPWERLW0.9750.9702818
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B51:09DPWERLWFLL0.93960.56041121
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B57:04VADHGRQRDPW0.99990.6438314
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B27:09QRDPWERLWFL0.99980.5076920
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B57:02VADHGRQRDPW0.99950.8718314
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:50RQRDPWERLWF0.99940.9579819
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:35RQRDPWERLWF0.99930.9199819
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:24RQRDPWERLWF0.9990.9574819
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:68RQRDPWERLWF0.99720.7629819
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:54RQRDPWERLWF0.99190.9281819
ARRB1-GDPD5chr1175062632chr1175173934118HLA-B15:53RQRDPWERLWF0.98790.9397819

Top

Potential FusionNeoAntigen Information of ARRB1-GDPD5 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ARRB1-GDPD5_75062632_75173934.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ARRB1-GDPD5chr1175062632chr1175173934118DRB1-1332PATVADHGRQRDPWE015
ARRB1-GDPD5chr1175062632chr1175173934118DRB1-1348PATVADHGRQRDPWE015
ARRB1-GDPD5chr1175062632chr1175173934118DRB1-1375PATVADHGRQRDPWE015

Top

Fusion breakpoint peptide structures of ARRB1-GDPD5

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3015GPEDTGKWERLWFLARRB1GDPD5chr1174993005chr1175173934512
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3336HGRQRDPWERLWFLARRB1GDPD5chr1175062632chr1175173934118

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ARRB1-GDPD5

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3015GPEDTGKWERLWFL-7.9962-8.1096
HLA-B14:023BVN3015GPEDTGKWERLWFL-5.70842-6.74372
HLA-B52:013W393015GPEDTGKWERLWFL-6.83737-6.95077
HLA-B52:013W393015GPEDTGKWERLWFL-4.4836-5.5189
HLA-A11:014UQ23015GPEDTGKWERLWFL-10.0067-10.1201
HLA-A11:014UQ23015GPEDTGKWERLWFL-9.03915-10.0745
HLA-A24:025HGA3015GPEDTGKWERLWFL-6.56204-6.67544
HLA-A24:025HGA3015GPEDTGKWERLWFL-5.42271-6.45801
HLA-B44:053DX83015GPEDTGKWERLWFL-7.85648-8.89178
HLA-B44:053DX83015GPEDTGKWERLWFL-5.3978-5.5112
HLA-A02:016TDR3015GPEDTGKWERLWFL-3.37154-4.40684
HLA-B14:023BVN3336HGRQRDPWERLWFL-7.15543-7.26883
HLA-B14:023BVN3336HGRQRDPWERLWFL-4.77435-5.80965
HLA-B52:013W393336HGRQRDPWERLWFL-6.80875-6.92215
HLA-B52:013W393336HGRQRDPWERLWFL-4.20386-5.23916
HLA-A11:014UQ23336HGRQRDPWERLWFL-7.5194-8.5547
HLA-A11:014UQ23336HGRQRDPWERLWFL-6.9601-7.0735
HLA-A24:025HGA3336HGRQRDPWERLWFL-7.52403-7.63743
HLA-A24:025HGA3336HGRQRDPWERLWFL-5.82433-6.85963
HLA-B27:056PYJ3336HGRQRDPWERLWFL-3.28285-4.31815
HLA-B44:053DX83336HGRQRDPWERLWFL-5.91172-6.94702
HLA-B44:053DX83336HGRQRDPWERLWFL-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ARRB1-GDPD5

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ARRB1-GDPD5chr1174993005chr11751739341120GKWERLWFLGGGAAGTGGGAGCGCCTCTGGTTCCTG
ARRB1-GDPD5chr1174993005chr1175173934314LQPGPEDTGKWCTGCAGCCGGGGCCCGAAGACACGGGGAAGTGG
ARRB1-GDPD5chr1174993005chr1175173934414QPGPEDTGKWCAGCCGGGGCCCGAAGACACGGGGAAGTGG
ARRB1-GDPD5chr1174993005chr1175173934718PEDTGKWERLWCCCGAAGACACGGGGAAGTGGGAGCGCCTCTGG
ARRB1-GDPD5chr1174993005chr1175173934918DTGKWERLWGACACGGGGAAGTGGGAGCGCCTCTGG
ARRB1-GDPD5chr1175062632chr11751739341020RDPWERLWFLAGGGACCCGTGGGAGCGCCTCTGGTTCCTG
ARRB1-GDPD5chr1175062632chr11751739341119DPWERLWFGACCCGTGGGAGCGCCTCTGGTTC
ARRB1-GDPD5chr1175062632chr11751739341120DPWERLWFLGACCCGTGGGAGCGCCTCTGGTTCCTG
ARRB1-GDPD5chr1175062632chr11751739341121DPWERLWFLLGACCCGTGGGAGCGCCTCTGGTTCCTGCTC
ARRB1-GDPD5chr1175062632chr1175173934314VADHGRQRDPWGTCGCGGACCATGGGCGACAAAGGGACCCGTGG
ARRB1-GDPD5chr1175062632chr1175173934716GRQRDPWERGGGCGACAAAGGGACCCGTGGGAGCGC
ARRB1-GDPD5chr1175062632chr1175173934717GRQRDPWERLGGGCGACAAAGGGACCCGTGGGAGCGCCTC
ARRB1-GDPD5chr1175062632chr1175173934817RQRDPWERLCGACAAAGGGACCCGTGGGAGCGCCTC
ARRB1-GDPD5chr1175062632chr1175173934818RQRDPWERLWCGACAAAGGGACCCGTGGGAGCGCCTCTGG
ARRB1-GDPD5chr1175062632chr1175173934819RQRDPWERLWFCGACAAAGGGACCCGTGGGAGCGCCTCTGGTTC
ARRB1-GDPD5chr1175062632chr1175173934917QRDPWERLCAAAGGGACCCGTGGGAGCGCCTC
ARRB1-GDPD5chr1175062632chr1175173934918QRDPWERLWCAAAGGGACCCGTGGGAGCGCCTCTGG
ARRB1-GDPD5chr1175062632chr1175173934919QRDPWERLWFCAAAGGGACCCGTGGGAGCGCCTCTGGTTC
ARRB1-GDPD5chr1175062632chr1175173934920QRDPWERLWFLCAAAGGGACCCGTGGGAGCGCCTCTGGTTCCTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ARRB1-GDPD5chr1175062632chr1175173934015PATVADHGRQRDPWECCTGCGACCGTCGCGGACCATGGGCGACAAAGGGACCCGTGGGAG

Top

Information of the samples that have these potential fusion neoantigens of ARRB1-GDPD5

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LUADARRB1-GDPD5chr1174993005ENST00000360025chr1175173934ENST00000336898TCGA-MP-A4TC
SKCMARRB1-GDPD5chr1175062632ENST00000360025chr1175173934ENST00000336898TCGA-FS-A1Z4-06A

Top

Potential target of CAR-T therapy development for ARRB1-GDPD5

check button Predicted 3D structure. We used RoseTTAFold.
38_ARRB1-GDPD5_t000_.e2e.pdb


check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneGDPD5chr11:74993005chr11:75173934ENST00000336898217126_1460606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000336898217161_1810606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000336898217193_2130606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000033689821743_630606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000336898217497_5170606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000033689821790_1100606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000376282013126_1460487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000376282013161_1810487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000376282013193_2130487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000037628201343_630487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000376282013497_5170487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000037628201390_1100487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000526177013126_1460468.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000526177013161_1810468.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000526177013193_2130468.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000052617701343_630468.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000526177013497_5170468.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000052617701390_1100468.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000529721318126_1460606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000529721318161_1810606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000529721318193_2130606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000052972131843_630606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000529721318497_5170606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000052972131890_1100606.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533784012126_1460487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533784012161_1810487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533784012193_2130487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000053378401243_630487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533784012497_5170487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000053378401290_1100487.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533805012126_1460361.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533805012161_1810361.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533805012193_2130361.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000053380501243_630361.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST00000533805012497_5170361.0TransmembraneHelical
TgeneGDPD5chr11:74993005chr11:75173934ENST0000053380501290_1100361.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000336898217126_1460606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000336898217161_1810606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000336898217193_2130606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000033689821743_630606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000336898217497_5170606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000033689821790_1100606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000376282013126_1460487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000376282013161_1810487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000376282013193_2130487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000037628201343_630487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000376282013497_5170487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000037628201390_1100487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000526177013126_1460468.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000526177013161_1810468.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000526177013193_2130468.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000052617701343_630468.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000526177013497_5170468.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000052617701390_1100468.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000529721318126_1460606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000529721318161_1810606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000529721318193_2130606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000052972131843_630606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000529721318497_5170606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000052972131890_1100606.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533784012126_1460487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533784012161_1810487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533784012193_2130487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000053378401243_630487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533784012497_5170487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000053378401290_1100487.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533805012126_1460361.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533805012161_1810361.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533805012193_2130361.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000053380501243_630361.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST00000533805012497_5170361.0TransmembraneHelical
TgeneGDPD5chr11:74993006chr11:75173934ENST0000053380501290_1100361.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000336898217126_1460606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000336898217161_1810606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000336898217193_2130606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000033689821743_630606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000336898217497_5170606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000033689821790_1100606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000376282013126_1460487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000376282013161_1810487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000376282013193_2130487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000037628201343_630487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000376282013497_5170487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000037628201390_1100487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000526177013126_1460468.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000526177013161_1810468.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000526177013193_2130468.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000052617701343_630468.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000526177013497_5170468.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000052617701390_1100468.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000529721318126_1460606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000529721318161_1810606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000529721318193_2130606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000052972131843_630606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000529721318497_5170606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000052972131890_1100606.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533784012126_1460487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533784012161_1810487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533784012193_2130487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000053378401243_630487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533784012497_5170487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000053378401290_1100487.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533805012126_1460361.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533805012161_1810361.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533805012193_2130361.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000053380501243_630361.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST00000533805012497_5170361.0TransmembraneHelical
TgeneGDPD5chr11:75062632chr11:75173934ENST0000053380501290_1100361.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result
ARRB1chr1174993005ENST00000360025GDPD5chr1175173934ENST00000336898
ARRB1chr1174993005ENST00000393505GDPD5chr1175173934ENST00000336898
ARRB1chr1175062632ENST00000360025GDPD5chr1175173934ENST00000336898
ARRB1chr1175062632ENST00000393505GDPD5chr1175173934ENST00000336898

Top

Related Drugs to ARRB1-GDPD5

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ARRB1-GDPD5

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource